OGNHealthcare · Drug Manufacturers - GeneralThe 4 Wall Street analysts covering Organon & Co. hold a median 12-month price target of $9 — -34.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 28 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Organon & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (33): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −34.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Apr 2026 | BNP Paribas | Downgrade | Neutral | $12 → $14 |
| 28 Apr 2026 | Piper Sandler | Upgrade | Neutral | $5.00 → $14 |
| 24 Feb 2026 | Barclays | Maintains | Underweight | — |
| 9 Dec 2025 | Barclays | Initiates | Underweight | — |
| 11 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 11 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 5 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 9 Apr 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 Feb 2025 | Barclays | Maintains | Overweight | — |
| 14 Feb 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 Sept 2024 | JP Morgan | Downgrade | Underweight | — |
| 6 May 2024 | Goldman Sachs | Maintains | Neutral | — |
| 3 May 2024 | Goldman Sachs | Maintains | Neutral | — |
| 29 Apr 2024 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2024 | Goldman Sachs | Maintains | Neutral | — |
| 22 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 3 Nov 2023 | Goldman Sachs | Downgrade | Neutral | — |
| 25 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 11 Oct 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Organon & Co. returned +108.6% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 41% of US stocks
Cheaper than 78% of US stocks
Cheaper than 26% of US stocks
Cheaper than 48% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Higher than 67% of US stocks
Higher than 80% of US stocks
Higher than 56% of US stocks
Higher than 84% of US stocks
Higher than 80% of US stocks
Higher than 66% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Organon & Co. has a market value of $3.6B and an enterprise value of $11.0B.
Revenue in the twelve months to 30 June 2026: $6.1B. The latest quarter shrank 2.3% year on year.
Net income over the same four quarters: $209.0M, a 3.4% net margin.
Diluted earnings per share, trailing twelve months: $0.77.
Free cash flow in the twelve months to 30 June 2026: $434.0M, after $170.0M of capital spending.
Organon & Co. spent $18.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.6×; forward P/E: 3.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.58%, paying out 10% of earnings.
Organon & Co. employs 10,000 people — $613K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| OGNOrganon & Co. | $3.6B | 77 |
| BIIBBiogen, Inc. | $36.1B | 76 |
| TNGXTango Therapeutics, Inc.* | $3.6B | 42 |
| RGCRegencell Bioscience Holdings Ltd.* | $3.6B | 21 |
| TARSTarsus Pharmaceuticals, Inc.* | $3.6B | 89 |
| CDNACareDx, Inc.* | $3.7B | 98 |
| AMLXAmylyx Pharmaceuticals, Inc.* | $3.5B | 57 |
* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Organon & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reports that Organon has recently been among the stocks most watched by Zacks.com users and suggests exploring what may lie ahead for the stock.
Why it matters — OGN watchers may note the recent attention the stock has received from Zacks.com users.
Organon plans to report its third-quarter 2026 financial results through its regularly scheduled Form 10-Q filing with the SEC. It also plans to disclose certain non-GAAP measures and reconciliations to comparable GAAP measures.
Why it matters — The filing will provide OGN watchers with the company’s third-quarter results and related financial measures.
Organon reported positive interim Phase 3 results for MIUDELLA®, a hormone-free intrauterine device, through six years of use, with no new safety signals. The results are to be presented at the 2026 Society of Family Planning Annual Meeting.
Why it matters — The results provide an update on the clinical development of an Organon product and its safety through six years of use.
Zacks Investment Research reports that users of Zacks.com have recently paid close attention to Organon & Co. (OGN). The article says this interest makes it worthwhile to examine the stock, but provides no further details in the excerpt.
Why it matters — OGN watchers may note the recent user attention, though the excerpt offers no specific company or stock developments.
Zacks.com users have recently shown increased attention toward Organon (OGN), making it a trending stock on the platform. The article highlights that it is important for investors to be aware of the facts that could impact the company's stock prospects.
Why it matters — OGN watchers would care because increased market attention and the highlighted factors affecting the stock's prospects may signal developments worth monitoring.
The 4 Wall Street analysts covering Organon & Co. have a median 12-month price target of $9, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Organon & Co., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Organon & Co. 77 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Organon & Co. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies -34.7% from the last close, and Ticker Nerd's factor model ranks Organon & Co. 77 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Organon & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
Organon & Co. returned +108.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines.
The most recent item we track (Zacks Investment Research, 26 Oct 2026): "Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It". Zacks Investment Research reports that Organon has recently been among the stocks most watched by Zacks.com users and suggests exploring what may lie ahead for the stock.
Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine. The company serves patients and healthcare providers in more than 140 markets through wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its women’s health business is a central part of the portfolio, supported by biosimilars and well-known legacy brands that address everyday treatment needs across multiple therapeutic areas. Organon & Co. operates as a diversified healthcare provider with a strong international footprint and a product mix designed to meet ongoing demand for prescription treatments and essential medicines.
CEO Mr. Kevin Ali · 10,000 employees · United States · https://www.organon.com
